Evaluation of the effectiveness and adverse events of oxycodone as a pain-relieving agent in 103 dogs with tumors: a retrospective study.
Saved in:
| Title: | Evaluation of the effectiveness and adverse events of oxycodone as a pain-relieving agent in 103 dogs with tumors: a retrospective study. |
|---|---|
| Authors: | Ko, Byung-Gee1 (AUTHOR), Kim, Tae-Hyun1 (AUTHOR), Namkung, Hyun1 (AUTHOR), Lee, Hye-Gyu1 (AUTHOR), Kang, Young-Jun1 (AUTHOR), Youn, Ga-Hee1 (AUTHOR), Seo, Kyoung-Won1 (AUTHOR), Youn, Hwa-Young1 (AUTHOR), Ryu, Min-Ok1 (AUTHOR) apple963@snu.ac.kr |
| Source: | BMC Veterinary Research. 10/2/2025, Vol. 21 Issue 1, p1-11. 11p. |
| Document Type: | Article |
| Subjects: | Oxycodone, Analgesic effectiveness, Tumors, Analgesia, Dogs, Veterinary medicine, Drug side effects, Retrospective studies |
| Author-Supplied Keywords: | Analgesic Cancer Canine Combination Metastasis Pain |
| Abstract: | Background: Oxycodone, a semi-synthetic opioid, has been widely used in human medicine for the management of tumor-related pain due to its potent analgesic properties. This study aimed to evaluate the efficacy and safety of oxycodone in managing tumor-related pain in dogs, addressing the current lack of research on effective analgesic options for canine cancer dogs. Medical records of 103 tumor-bearing dogs treated with oxycodone were retrospectively reviewed. Results: Oxycodone demonstrated an analgesic effect ranging from 23.1 to 63.6%, depending on the anatomical origin of the tumor. Improvement was observed in 67.7% of dogs with metastatic lesions. In the monotherapy group, the mean pain relief score increased from 8.73 ± 1.27 before treatment to 9.65 ± 1.53 after administration (p < 0.0001). In the combination therapy group, score rose from 8.75 ± 1.20 to 9.83 ± 1.87 (p = 0.0002). Across the entire canine patient cohort, the mean pain relief score increased from 8.74 ± 1.23 to 9.74 ± 1.70 following treatment (p < 0.0001). Adverse effects included lethargy (n = 6), diarrhea (n = 2), vomiting (n = 1), tachypnea (n = 1), and stargazing (n = 1). All were self-limiting and resolved after discontinuation of the drug. Conclusions and clinical importance: Oxycodone demonstrated an overall favorable analgesic profile and could be a well-tolerated and promising pain management solution, both as monotherapy and in combination therapy, for tumor-related pain in dogs, including those with advanced-stage tumors. [ABSTRACT FROM AUTHOR] |
| Copyright of BMC Veterinary Research is the property of BioMed Central and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Author Affiliations: | 1https://ror.org/04h9pn542 Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science, Seoul National University, 08826, Seoul, Republic of Korea |
| Full Text Word Count: | 7779 |
| ISSN: | 1746-6148 |
| DOI: | 10.1186/s12917-025-04987-3 |
| Accession Number: | 188451284 |
| Database: | Veterinary Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Oxycodone, a semi-synthetic opioid, has been widely used in human medicine for the management of tumor-related pain due to its potent analgesic properties. This study aimed to evaluate the efficacy and safety of oxycodone in managing tumor-related pain in dogs, addressing the current lack of research on effective analgesic options for canine cancer dogs. Medical records of 103 tumor-bearing dogs treated with oxycodone were retrospectively reviewed. Results: Oxycodone demonstrated an analgesic effect ranging from 23.1 to 63.6%, depending on the anatomical origin of the tumor. Improvement was observed in 67.7% of dogs with metastatic lesions. In the monotherapy group, the mean pain relief score increased from 8.73 ± 1.27 before treatment to 9.65 ± 1.53 after administration (p < 0.0001). In the combination therapy group, score rose from 8.75 ± 1.20 to 9.83 ± 1.87 (p = 0.0002). Across the entire canine patient cohort, the mean pain relief score increased from 8.74 ± 1.23 to 9.74 ± 1.70 following treatment (p < 0.0001). Adverse effects included lethargy (n = 6), diarrhea (n = 2), vomiting (n = 1), tachypnea (n = 1), and stargazing (n = 1). All were self-limiting and resolved after discontinuation of the drug. Conclusions and clinical importance: Oxycodone demonstrated an overall favorable analgesic profile and could be a well-tolerated and promising pain management solution, both as monotherapy and in combination therapy, for tumor-related pain in dogs, including those with advanced-stage tumors. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 17466148 |
| DOI: | 10.1186/s12917-025-04987-3 |